337 related articles for article (PubMed ID: 33414495)
1. Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study.
Štorkánová H; Oreská S; Špiritović M; Heřmánková B; Bubová K; Komarc M; Pavelka K; Vencovský J; Distler JHW; Šenolt L; Bečvář R; Tomčík M
Sci Rep; 2021 Jan; 11(1):1. PubMed ID: 33414495
[TBL] [Abstract][Full Text] [Related]
2. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
[TBL] [Abstract][Full Text] [Related]
3. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.
Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Toyama T; Takahashi T; Ichimura Y; Noda S; Akamata K; Saigusa R; Miyazaki M; Kuwano Y; Yanaba K; Yoshizaki A; Sato S
J Dermatol; 2018 Dec; 45(12):1425-1433. PubMed ID: 30289572
[TBL] [Abstract][Full Text] [Related]
4. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM
Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288
[TBL] [Abstract][Full Text] [Related]
7. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
Volkmann ER; Tashkin DP; Sim M; Li N; Goldmuntz E; Keyes-Elstein L; Pinckney A; Furst DE; Clements PJ; Khanna D; Steen V; Schraufnagel DE; Arami S; Hsu V; Roth MD; Elashoff RM; Sullivan KM;
Ann Rheum Dis; 2019 Jan; 78(1):122-130. PubMed ID: 30409830
[TBL] [Abstract][Full Text] [Related]
8. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
9. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
Le Gouellec N; Duhamel A; Perez T; Hachulla AL; Sobanski V; Faivre JB; Morell-Dubois S; Lambert M; Hatron PY; Hachulla E; Béhal H; Matran R; Launay D; Remy-Jardin M
PLoS One; 2017; 12(8):e0181692. PubMed ID: 28763468
[TBL] [Abstract][Full Text] [Related]
10. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
11. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis.
Poormoghim H; Moradi Lakeh M; Mohammadipour M; Sodagari F; Toofaninjed N
Rheumatol Int; 2012 Aug; 32(8):2431-44. PubMed ID: 21691743
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.
Panopoulos ST; Bournia VK; Trakada G; Giavri I; Kostopoulos C; Sfikakis PP
Lung; 2013 Oct; 191(5):483-9. PubMed ID: 23925736
[TBL] [Abstract][Full Text] [Related]
14. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
16. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
[TBL] [Abstract][Full Text] [Related]
17. Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease.
Saigusa R; Asano Y; Nakamura K; Yamashita T; Ichimura Y; Takahashi T; Toyama T; Taniguchi T; Yoshizaki A; Miyazaki M; Tamaki Z; Sato S
Mod Rheumatol; 2017 Jul; 27(4):618-622. PubMed ID: 27538472
[TBL] [Abstract][Full Text] [Related]
18. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.
Beretta L; Caronni M; Raimondi M; Ponti A; Viscuso T; Origgi L; Scorza R
Clin Rheumatol; 2007 Feb; 26(2):168-72. PubMed ID: 16614793
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.
Volkmann ER; Tashkin DP; Sim M; Li N; Khanna D; Roth MD; Clements PJ; Hoffmann-Vold AM; Furst DE; Kim G; Goldin J; Elashoff RM
J Rheumatol; 2019 Oct; 46(10):1316-1325. PubMed ID: 30770517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
